Definium Therapeutics (DFTX) Stock Overview
A clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DFTX Community Fair Values
Create NarrativeSee what 86 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Definium Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.28 |
| 52 Week High | US$49.70 |
| 52 Week Low | US$8.77 |
| Beta | 2.24 |
| 1 Month Change | -12.54% |
| 3 Month Change | 8.57% |
| 1 Year Change | 311.74% |
| 3 Year Change | 994.15% |
| 5 Year Change | 8.21% |
| Change since IPO | 351.03% |
Recent News & Updates
Recent updates
Narrative Update • Sep 18
DFTX: Phase 3 Mood Disorder Wins And FDA Breakthroughs Will Recast Psychedelic Treatment Potential
Analysts have lifted their average price target for Definium Therapeutics from about $67.47 to roughly $71.65, citing updated models that reflect positive Phase 3 Panorama data for generalized anxiety disorder and increased confidence in the commercial potential of DT120 across mood disorders. Analyst Commentary Recent research coverage on Definium Therapeutics has been highly active, with multiple firms revisiting their models after Phase 3 Emerge, Voyage and Panorama readouts for DT120 across major depressive disorder and generalized anxiety disorder.
Narrative Update • Sep 04
DFTX: Phase 3 Mood Disorder Wins And Psychedelic Policy Should Drive Returns
Analysts have nudged their fair value estimate for Definium Therapeutics to $52 from $50, citing stronger assumptions around DT120’s revenue potential and margins after a series of higher price targets across the Street, following positive Phase 3 data in major depressive disorder and generalized anxiety disorder. Analyst Commentary Street research on Definium Therapeutics over the past several months has clustered around one core theme.Narrative Update • Aug 21
DFTX: Phase 3 Mood Disorder Data Will Recast Psychedelic Treatment Potential
Definium Therapeutics' analyst fair value estimate has moved from $59.47 to $67.47 as analysts factor in stronger Phase 3 data for DT120 in major depressive disorder and generalized anxiety disorder, updated approval probabilities, and larger modeled commercial opportunities reflected in a series of higher Street price targets. Analyst Commentary Street research on Definium Therapeutics has shifted noticeably in recent months, with several firms updating valuation models for DT120 in major depressive disorder and generalized anxiety disorder following Phase 3 data and capital raising activity.Seeking Alpha • Aug 12
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst
Summary Definium Therapeutics remains a 'Strong Buy' following positive phase 3 VOYAGE data for DT120 ODT in generalized anxiety disorder [GAD]. The company's DT120 ODT achieved a statistically significant -5.4 placebo-adjusted reduction in HAM-A score at 12 weeks in GAD, highlighting best-in-class potential. Upcoming catalysts include phase 3 PANORAMA GAD data in September 2026 and ASCEND MDD topline results in 2027. The company is well-capitalized with $1.1B in cash, supporting operations into 2030 and multiple late-stage neuropsychiatric programs. Read the full article on Seeking AlphaNarrative Update • Aug 07
DFTX: Phase 3 Mood Disorder Data And Psychedelic Policy Will Shape Returns
Analysts lifted their fair value estimate for Definium Therapeutics to $50, citing a series of higher Street price targets in the $57 to $74 range. These targets reflect increased conviction in DT120 following strong Phase 3 data in major depressive disorder and generalized anxiety disorder, a wider anticipated patient footprint, and a regulatory backdrop that is viewed as more supportive for psychedelic treatments.Narrative Update • Jul 24
DFTX: Phase 3 Depression Success Will Recast Psychedelic Treatment Potential
Analysts have raised their fair value estimate for Definium Therapeutics from about $35.23 to roughly $59.47, citing increased confidence in DT120 following Phase 3 major depressive disorder data, as well as a more favorable regulatory stance on psychedelic therapies, as key factors behind the higher price targets across the Street. Analyst Commentary Street commentary on Definium Therapeutics centers on how DT120's Phase 3 data in major depressive disorder feeds into valuation, execution risk, and the broader outlook for psychedelic-based therapies.
Narrative Update • Jul 10
DFTX: Phase 3 Depression Data Will Drive Repricing Of Psychedelic Franchise
Definium Therapeutics' analyst fair value estimate has moved from about $63.18 to $72.73. This reflects analysts' updated price targets around $57 to $74 after stronger than expected DT120 Phase 3 data in major depressive disorder and generalized anxiety disorder indications, as well as model changes following the recent $805m capital raise.Narrative Update • Jun 26
DFTX: Phase 3 Depression Data Will Likely Prove Priced In
Definium Therapeutics' updated fair value estimate has moved from $20.00 to about $35.66 as analysts raise price targets into the $57 to $74 range, citing strong Phase III EMERGE data for DT120 in major depressive disorder and increased confidence in the program across additional indications. Analyst Commentary Recent Street research on Definium Therapeutics centers on the Phase III EMERGE data for DT120 in major depressive disorder, with multiple firms updating their models and adjusting price targets to reflect the reported effect size, durability of response, and safety profile.New Narrative • Apr 02
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 19
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?New Narrative • Mar 04
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 21
Mind Medicine: Initiating Hold Rating Due To Regulatory Challenges
Summary Initiating coverage on Mind Medicine with a Hold rating due to regulatory uncertainties around rescheduling Schedule I compounds for medical use. Despite strong cash resources and promising Phase 3 trials, regulatory delays could hinder MNMD's patient access and market entry. The global GAD, MDD, and ASD markets present significant growth opportunities, but MM120 faces competition and unique safety and scheduling issues. Positive Phase 3 outcomes could drive regulatory progress, but until FDA and DEA clear rescheduling, broad patient access and reimbursement remain uncertain. Read the full article on Seeking AlphaSeeking Alpha • Jan 29
MindMed's LSD Anxiety Drug: Revisiting, Rethinking, But Maintaining My 'Hold' Call
Summary Mind Medicine (MindMed) Inc.'s stock has surged over 160% since my October 2022 “Hold” call, driven by positive Phase 2b data for MM120 in treating GAD. Despite financial stability and promising Phase 3 trials, significant hurdles remain, including DEA rescheduling of LSD and FDA approval challenges. The company faces issues with patenting naturally occurring substances and potential reluctance from insurers and physicians to adopt psychedelic therapies. While MindMed shows progress, I remain cautious due to regulatory and commercial obstacles, maintaining my “Hold” rating on MNMD amidst ongoing uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate
Summary Mind Medicine (MindMed) Inc. is advancing MM-120 for GAD with two phase 3 trials, VOYAGE and PANORAMA, starting in late 2024 and early 2025. MM-120 is also being tested for MDD in the phase 3 EMERGE study, starting in the first half of 2025, with data expected in late 2026. The company has secured funding through 2027, following a public offering, and burns approximately $24.5 million in cash per quarter. Investors should watch for key milestones in 2026 and consider risks related to trial outcomes and regulatory approval for MM-120 and MM-402. Read the full article on Seeking AlphaSeeking Alpha • Aug 15
Psychedelic Stocks: Focus On Their Cash
Summary Jason Najum covers the psychedelic space and contextualizes recent news around the FDA, MDMA, PTSD, and Lykos Therapeutics. Why it may be a blessing in disguise for Cybin, COMPASS Pathways, and MindMed despite setbacks. Major players in the psychedelic medicine space are well-funded, moving into Phase 3 trials, with potential for significant milestones in the near future. Read the full article on Seeking AlphaSeeking Alpha • Jun 05
MindMed: Despite MDMA Setback, Still Hope In Light Of Differentiating Factors
Summary Mind Medicine's (MindMed) results from phase 1 investigator-initiated trial, using MM-402 for the treatment of patients with Autism Spectrum Disorder, expected Q2 of 2024. The primary endpoint of the phase 2b MMED008 study met with statistical significance of HAM-A score over a 4-week period; Patients were given MM-120 to treat GAD. The global Generalized Anxiety Disorder treatment market is expected to reach $4.26 billion by 2033. MindMed has a backup candidate in its pipeline, MM-402, which still uses MDMA targeting for disorders, but with an improved safety profile; this would be MDMA types R[-]-MDMA, S[+]-MDMA and R/S-MDMA. Read the full article on Seeking AlphaSeeking Alpha • Apr 04
Mind Medicine: GAD Program Success Continues With BTD And Positive Treatment Data
Summary Mind Medicine (MindMed) Inc. achieved positive results from phase 2b MMED008 study using MM-120 for the treatment of patients with generalized anxiety disorder. End-of-phase 2 meeting with the FDA for MM-120 program for GAD 1st half of 2024 and phase 3 trial initiation expected 2nd half of 2024. The global generalized anxiety disorder treatment market is expected to reach $4.26 billion by 2033. MM-402 is being advanced in a phase 1 study for the treatment of patients with ASD with results expected 1st half of 2024; The global autism spectrum disorder market could grow to $3.42 billion by 2030. Read the full article on Seeking AlphaShareholder Returns
| DFTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.4% | 1.4% | 1.8% |
| 1Y | 311.7% | 49.6% | 13.3% |
Return vs Industry: DFTX exceeded the US Pharmaceuticals industry which returned 49.6% over the past year.
Return vs Market: DFTX exceeded the US Market which returned 13.3% over the past year.
Price Volatility
| DFTX volatility | |
|---|---|
| DFTX Average Weekly Movement | 16.7% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DFTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DFTX's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 106 | Rob Barrow | definiumtx.com |
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
Definium Therapeutics, Inc. Fundamentals Summary
| DFTX fundamental statistics | |
|---|---|
| Market cap | US$5.21b |
| Earnings (TTM) | -US$353.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.9x
P/E RatioIs DFTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DFTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$353.79m |
| Earnings | -US$353.78m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.0% |
How did DFTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 03:40 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Definium Therapeutics, Inc. is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Chen | Baird |
| null null | Baird |
| Joel Beatty | Baird |